NeuroSense Therapeutics Ltd. Private Placement
Ticker: NRSNW · Form: 6-K · Filed: Sep 4, 2025 · CIK: 1875091
Sentiment: neutral
Topics: private-placement, capital-raise, shares
TL;DR
NeuroSense just sold 333,334 shares privately on Sept 4th.
AI Summary
On September 4, 2025, NeuroSense Therapeutics Ltd. entered into a Securities Purchase Agreement with a single investor to issue and sell 333,334 ordinary shares in a private placement. The company is based in Herzliya, Israel.
Why It Matters
This private placement indicates the company is raising capital, potentially to fund ongoing research and development or operational expenses.
Risk Assessment
Risk Level: medium — Private placements can sometimes signal a need for immediate capital, which may indicate underlying financial pressures or specific project funding requirements.
Key Numbers
- 333,334 — Ordinary Shares (Number of shares sold in private placement)
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer and issuer of shares
- September 4, 2025 (date) — Date of Securities Purchase Agreement
- Securities Purchase Agreement (document) — Agreement for the private placement
- 333,334 (number) — Number of ordinary shares to be issued
FAQ
What is the total value of the private placement?
The filing does not specify the dollar amount of the private placement, only the number of shares (333,334).
Who is the single investor in this private placement?
The filing refers to the investor only as 'the Purchaser' and does not disclose their identity.
What is the purpose of this private placement?
The filing states the company agreed to issue and sell shares in the offering but does not specify the intended use of the proceeds.
What type of shares are being issued?
The filing states that the company agreed to issue and sell 'ordinary shares'.
When was the Securities Purchase Agreement entered into?
The Securities Purchase Agreement was entered into on September 4, 2025.
Filing Stats: 891 words · 4 min read · ~3 pages · Grade level 14.1 · Accepted 2025-09-04 08:59:39
Key Financial Figures
- $1.50 — ). The purchase price of each Share was $1.50. The gross proceeds to the Company from
- $0.5 m — fering are expected to be approximately $0.5 million, before deducting offering expens
- $500,000 — ldquo;NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market
Filing Documents
- ea0255987-6k_neurosense.htm (6-K) — 19KB
- ea025598701ex10-1_neuro.htm (EX-10.1) — 119KB
- ea025598701ex99-1_neuro.htm (EX-99.1) — 11KB
- 0001213900-25-084292.txt ( ) — 150KB
Forward-Looking Statements
Forward-Looking Statements This Report on Form 6-K contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For example, this Report on Form 6-K states that the Offering is expected to close on September 8, 2025. In fact, the closing of the Offering is subject to various conditions and contingencies as are customary in securities purchase agreements in the United States. If these conditions are not satisfied or the specified contingencies do not occur, this Offering may not close. For this reason, among others, you should not place undue reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the date of this Report. 2 Exhibit Index Exhibit No. Description 10.1 Form of Securities Purchase Agreement, dated as of September 4, 2025, by and between NeuroSense Therapeutics Ltd. and the purchaser identified on the signature pages thereto 99.1 Press Release, dated September 4, 2025 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: September 4, 2025 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 4